Using ultrasound and RNA-loaded nanoparticles to deliver potent medicine to brain tumors
RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways.
Mostly.
So far, these promising drugs haven t been very useful in getting through to the well-protected brain to treat tumors or other maladies.
Now a multi-institutional team of researchers, led by Costas Arvanitis at the Georgia Institute of Technology and Emory University, has figured out a way: using ultrasound and RNA-loaded nanoparticles to get through the protective blood-brain barrier and deliver potent medicine to brain tumors.
Georgia Institute of Technology
RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways.
Mostly.
So far, these promising drugs haven’t been very useful in getting through to the well-protected brain to treat tumors or other maladies.
Now a multi-institutional team of researchers, led by Costas Arvanitis at the Georgia Institute of Technology and Emory University, has figured out a way: using ultrasound and RNA-loaded nanoparticles to get through the protective blood-brain barrier and deliver potent medicine to brain tumors.
E-Mail
IMAGE: Georgia Tech Mechanical Engineering Ph.D. student Yutong Guo (left) and her mentor, assistant professor Costas Arvanitis, have developed a way to use ultrasonics to treat brain disease. view more
Credit: Ashley Ritchey, Georgia Tech
RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways.
Mostly.
So far, these promising drugs haven t been very useful in getting through to the well-protected brain to treat tumors or other maladies.
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.